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SMethods: 2,621 patients underwent TAVR with the SAPIEN heart valve via TF
(N¼1521) or TA (N¼1100) delivery routes between April 2007 and January 2012.
The study was divided into 2 time domains for this analysis, 1st half (2007 – 2009)
and 2nd half (2010 – 2012). The Shapes of the learning curves were assessed using
a semi-parametric mixed effects model.
Results: Figure 1A details the outcomes of the technical performance variables. Using
the date of implant, there appeared to be a signiﬁcant downward trend in procedure
times (Figure 1B), ﬂuoroscopy times and contrast volume. (Figure 1C and D) The
improvement in these parameters was particularly striking in TF cases p < 0.005.Conclusions: Our results demonstrate that in the PARTNER trial there is an important
TAVR learning curve with signiﬁcant improvement in procedural and performance
variables over time. Although the differences in primary operator skill sets between
TA and TF approaches may explain some of the observed heterogeneity in learning
curves, a critical volume of cases appears necessary to become proﬁcient in the safe
performance of TAVR, particularly via the TF route.
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Background: Acute Kidney injury (AKI) after cardiac surgery is associated with
increased mortality, but very few data exist on the occurrence of AKI associated with
Transcatheter Aortic Valve Implantation (TAVI). The objective of this study was to
determine the incidence and prognosis of AKI after percutaneous implantation of the
CoreValve aortic prosthesis.
Methods: Between April-2008 and January-2011, 223 patients with severe aortic
stenosis were treated with the CoreValve prosthesis. The AKI was deﬁned according
to Valve set by the Academic Research Consortium, as the absolute increase in serum
creatinine 0.3 mg/dl at 72 hours a percutaneous procedure.
Results: AKI was identiﬁed in 37 patients (16.6%) and none required renal
replacement therapy. After implantation there was a slight improvement in renal
function, baseline serum creatinine decreased from 1.290.5 mg/dl to 1.22 mg/dl,
P¼0.023 and glomerular ﬁltration rate (GFR) increased from 49.622 to 5223,
P¼0.015. In patients with AKI, the mortality at 30 days was 13.5 % compared to 1.6%
of patients without AKI, P¼0.001 and late mortality after a mean of 16.711 months
was 18.8% in those patients with AKI compared to 8.2% in those without AKI,
P¼0.068. In the multivariate analysis AKI was an independent predictor of cumulative
total mortality (HR¼3.516, 95% CI from 1.098 to 11.255, P¼0.034).
Conclusions: Deterioration of renal function in patients undergoing TAVI with the
CoreValve prosthesis is a serious and frequent complication. The occurrence of AKI
was associated with increase early mortality and also was a predictor of worse
outcomes in the long-term follow-up.
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Background: Accurate sizing of the aortic annulus is an important premise for
successful Transcatheter aortic valve implantation (TAVI). Multislice computed
tomography (MSCT) may have advantages over other imaging modalities, but there is
uncertainty whether 1) measurements should be performed in systole or diastole and
2) if calculation of the effective annulus diameter should be based on area orB228 JACC Vol 62/18/Suppl B j October 27–Novemberperimeter. Aim of our study was to compare MSCT results with direct intraoperative
sizing of the annulus.
Methods: Conventional aortic valve replacement was performed in 25 patients who
were primarily screened for TAVI, but were deemed inappropriate for several reasons,
and the annulus was measured intraoperatively after decalciﬁcation using metric
sizers. All patients had undergone transesophageal echocardiography (TEE) and
MSCT for TAVI workup and effective annulus diameter was determined derived by
area (AsysA, AdiaA) and perimeter (AsysP, AdiaP) in systole and diastole, respec-
tively. Additionally, potential change of strategy for the different approaches
compared to intraoperative annulus sizing in case of TAVI using the Edwards Sapien
XT valve was simulated.
Results: Best agreement with direct operative sizing (intraop) was observed for
AsysA in the Bland-Altman analysis (mean difference between intraop vs. AsysA
-0.17 mm, limits of agreement -1.98 – 1.64; intraop vs. AdiaA 0.65 mm, limits of
agreement -1.56 to 2.86; intraop vs. AsysP -0.92 mm, limits of agreement -2.81 to
0.97 and intraop vs. AdiaP -0.29 mm, limits of agreement -2.85 to 2.27), TEE 1.5 mm,
limits of agreement -2.77 to 2.27). Least change of strategy would have occurred with
AsysA (20%), followed by AdiaP (28%), AdiaA (30%) and AsysP (40%).
Conclusions: Compared to surgical sizing area derived measurement in systole
represents the best approach for annulus determination with least strategy change.
Perimeter derived measurement in systole may lead to overestimation of the true
annulus size.
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Background: The 18F Direct Flow Medical (DFM) THV has conformable sealing
rings which minimizes aortic regurgitation and permits full hemodynamic assessment
of valve performance prior to permanent implantation.
Methods: The DISCOVER trial was a prospective, multicenter evaluation of 100
patients who underwent TAVI with the DFM THV. Within this study, 3 patients were
at risk for receiving contrast media: 2 due to severe CKD (eGFR < 30 mL/min/1.73
m2) and 1 due to a recent hyperthyroid reaction to contrast. The valve was positioned
under ﬂuoroscopic and transesophageal guidance without aortography during either
positioning or to conﬁrm the ﬁnal position. Valve positioning was based on the
optimal angiographic projection as calculated by the pre-procedural multi-slice CT
scan. Precise optimization of valve position was performed to minimize transvalve
gradient and aortic regurgitation. Prior to ﬁnal implantation, transvalve hemodynamics
were assessed invasively and by TEE.
Results: The average age was 81 years. The baseline logistic EuroSCORE were 15,
18 and 24. LVEF was 33, 40, and 62%. The post procedure mean gradients were 7,
10, 11 mmHg. The ﬁnal AVA by echo was 1.70, 1.40 and 1.68 cm2. Total aortic
regurgitation post procedure was none or trace in all 3 patients. Total positioning and
assessment of valve performance time was 4, 6, and 12 minutes, and total skin to skin
procedure time were 29, 47, and 64 minutes. A 25mm valve was used in all 3. There
was 100% freedom from all cause mortality at 30 days. VARC deﬁned device success
was 100% and patient safety freedom from events was 100%. One had a permanent
pacemaker due to AV block. Contrast was only used to conﬁrm successful percuta-
neous closure of the femoral access site. The total contrast dose was 5, 8, 12 cc.
Baseline eGFR and creatinine was 28, 22, 74 mL/mn/1.73 m2 and 2.35, 2.98, and 1.03
mg/dL, respectively. Renal function was unchanged post procedure: eGFR¼25, 35,
and 96 mL/mn/1.73 m2 and creatinine¼2.58, 1.99, and 1.03 mg/dL, respectively.
Conclusions: The DFM THV provides the ability to perform TAVI with minimal or
no contrast. The precise and predictable implantation technique can be performed with
ﬂuoro and echo guidance.
TCT-751
Aortic Stenosis in the Elderly: number of TAVR candidates
Ruben L. J. Osnabrugge1, Darren Mylotte2, Stuart J. Head1,
Nicolas M Van Mieghem3, Vuyisile T. Nkomo4, Corinne Le Reun5, Ad J. Bogers1,
Nicolo Piazza6, A. Pieter Kappetein3
1Erasmus University Medical Center, Rotterdam, Netherlands, 2McGill University
Health Center, Royal Victoria Hospital, Montreal, Quebec, 3Erasmus MC, Rotterdam,
Netherlands, 4Mayo Clinic, Rochester, MN, 5Biostatistician, Carrigaline, Ireland,
6McGill University Health Center, Royal Victoria Hospital, Montreal, Canada
Background: Severe AS is a leading cause of morbidity and mortality in elderly.A
proportion of patients is now considered for transcatheter aortic valve replacement
(TAVR).We i) performed a meta-analysis on the prevalence of AS in the elderly and
ii) systematically estimated the number of candidates for TAVR.
Methods: A systematic search was conducted in multiple databases and prevalence
rates of patients (>75 years) were pooled.A model was based on a second systematic1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
